Small molecule drug developer Aria Pharmaceuticals (Palo Alto, Calif.) has announced that two investigational treatments for idiopathic pulmonary fibrosis (IPF), TXR-1002 and TXR-1007, demonstrated efficacy and tolerability in preclinical research.
Read more here.
![[Ro in Business Insider] 5 ways the election could upend digital health, according to 14 healthcare CEOs, investors, and policy experts](https://blog.ourcrowd.net/wp-content/themes/Extra/images/post-format-thumb-text.svg)
